VC
Vivo Capital Portfolio holdings
AUM
$977M
This Quarter Return
-2.85%
1 Year Return
+209.68%
3 Year Return
+1,480.07%
5 Year Return
+2,591.98%
10 Year Return
–
AUM
$1.08B
AUM Growth
+$1.08B
(-15%)
Cap. Flow
-$71.3M
Cap. Flow
% of AUM
-6.58%
Top 10 Holdings %
Top 10 Hldgs %
76.04%
Holding
46
New
4
Increased
2
Reduced
6
Closed
4
Top Buys
| 1 |
Erasca
ERAS
|
$15.9M |
| 2 |
Celcuity
CELC
|
$10M |
| 3 |
Abeona Therapeutics
ABEO
|
$7.81M |
| 4 |
Corbus Pharmaceuticals
CRBP
|
$7.55M |
| 5 |
Oric Pharmaceuticals
ORIC
|
$2.97M |
Top Sells
| 1 |
Soleno Therapeutics
SLNO
|
$44.9M |
| 2 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$20.8M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
$16.4M |
| 4 |
GTH
Genetron Holdings Limited ADS
GTH
|
$10.9M |
| 5 |
Savara
SVRA
|
$10.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Soleno Therapeutics
SLNO
$3.6B
| $299M | 27.58% | 7,316,851 -1,101,242 | -13% | -$44.9M |
|
2
Geron
GERN
$893M
| $115M | 10.66% | 27,225,292 | – | – |
|
3
Harmony Biosciences
HRMY
$2.12B
| $78.6M | 7.26% | 2,606,247 | – | – |
|
|
SVA
4
DELISTED
Sinovac Biotech, Ltd
SVA
| $76.3M | 7.05% | 11,800,000 | – | – |
|
5
Dyne Therapeutics
DYN
$1.92B
| $57.7M | 5.33% | 1,635,136 | – | – |
|
|
AVDL
6
Avadel Pharmaceuticals
AVDL
$1.43B
| $55.8M | 5.16% | 3,972,099 | – | – |
|
|
VRNA
7
Verona Pharma
VRNA
$9.16B
| $51.3M | 4.74% | 3,549,758 -60,419 | -2% | -$874K |
|
8
Terns Pharmaceuticals
TERN
$609M
| $42.1M | 3.89% | 6,182,992 -475,000 | -7% | -$3.23M |
|
9
ALX Oncology
ALXO
$62.7M
| $25.4M | 2.35% | 4,220,048 | – | – |
|
10
Viridian Therapeutics
VRDN
$1.5B
| $21.8M | 2.02% | 1,678,207 | – | – |
|
11
Astria Therapeutics
ATXS
$349M
| $21.2M | 1.96% | 2,329,027 | – | – |
|
|
SLN
12
Silence Therapeutics
SLN
$227M
| $21M | 1.94% | 1,105,454 | – | – |
|
13
Olema Pharmaceuticals
OLMA
$375M
| $20.3M | 1.87% | 1,873,704 | – | – |
|
14
Cogent Biosciences
COGT
$1.69B
| $18.9M | 1.75% | 2,244,941 | – | – |
|
|
15
Erasca
ERAS
$445M
| $15.9M | 1.47% | +6,756,756 | New | +$15.9M |
|
16
Tarsus Pharmaceuticals
TARS
$2.47B
| $15.4M | 1.42% | 565,550 | – | – |
|
17
Delcath Systems
DCTH
$385M
| $14M | 1.29% | 1,666,746 | – | – |
|
18
Rezolute
RZLT
$619M
| $12M | 1.11% | 2,797,704 | – | – |
|
|
19
Celcuity
CELC
$2.17B
| $10M | 0.92% | +610,500 | New | +$10M |
|
20
Sera Prognostics
SERA
$123M
| $9.77M | 0.9% | 1,650,440 | – | – |
|
|
CMPS
21
Compass Pathways
CMPS
$424M
| $9.71M | 0.9% | 1,608,000 | – | – |
|
22
Zai Lab
ZLAB
$3.68B
| $9.21M | 0.85% | 531,198 | – | – |
|
|
23
Oric Pharmaceuticals
ORIC
$994M
| $8.98M | 0.83% | 1,269,676 +419,995 | +49% | +$2.97M |
|
|
RGLS
24
DELISTED
Regulus Therapeutics
RGLS
| $8.93M | 0.82% | 5,000,000 | – | – |
|
|
25
Abeona Therapeutics
ABEO
$350M
| $7.81M | 0.72% | +1,842,751 | New | +$7.81M |
|